Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...
36mon MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback